Gedeon Richter account plan
Pharmaceutical manufacturing and research
At a glance
Gedeon Richter is a Budapest-listed pharmaceutical group with FY2025 revenues of HUF 928,962m (EUR 2,336.1m) and 11,955 employees in 50+ countries.
Gedeon Richter Plc. is a Hungarian pharmaceutical group, founded in 1901 and listed in Budapest, that develops, makes and sells original drugs, generics, biosimilars and contract biologics manufacturing (CDMO). It is organised in an Innovative pillar (Women's Healthcare and Neuropsychiatry) and an Affordable pillar (General Medicines and Biotechnology), and sells in more than 50 countries; the USA, Russia, Hungary, Poland and Germany are its top markets. In FY2025 it reported revenues of HUF 928,962m (EUR 2,336.1m, +8.3%), EBIT of HUF 292,851m and net profit of HUF 232,335m. It had 11,955 employees at end-2025, including more than 1,100 in R&D. Its largest shareholders are two Hungarian foundations with 10.00% each, and international investors held 59.66% of the shares.
Business units
Women's Healthcare (WHC)
HUF 328,573m in FY2025, about 36% of pharma revenuesContraception, fertility, menopause and uterine fibroids/endometriosis products, led by Ryeqo (+90.5%), Lenzetto (+66.7%) and Drovelis (+47.0%) in FY2025. The estetrol (E4) platform from the Mithra deal gave the menopause therapy FYLREVY, launched in pilot European markets in 2026; the FDA accepted its US filing. In Q1-Q3 2026 revenues were HUF 251.5bn (+10.9% CER).
Neuropsychiatry (CNS)
HUF 264,701m in FY2025, about 29% of pharma revenuesBuilt on cariprazine, sold as VRAYLAR in the US by AbbVie and as REAGILA in Europe; it earned an 87.3% Clean EBIT margin in FY2025 and is the group's profit engine. US exclusivity runs to 17 March 2030. In Q1-Q3 2026 revenues were HUF 202.0bn (+19% CER), and the pipeline includes ABBV-932 with AbbVie and Richter's own RGH-202.
General Medicines (GM)
HUF 249,534m in FY2025, 27.3% of pharma revenuesBranded and generic medicines across Central and Eastern Europe and the CIS (pain and neurology, cardiology, OTC, blood and metabolic). Revenues fell 0.5% in FY2025 after a MYDOCALM/MYDETON out-of-stock and injectables manufacturing issues; Q1-Q3 2026 revenues were HUF 176.1bn (+1.4% CER) with OTC down 18.7%. GLP-1 generics (semaglutide with Adalvo and Hetero) are a priority.
Biotechnology (BIO)
HUF 64,157m in FY2025, about 7% of pharma revenuesBiosimilars (teriparatide, denosumab, tocilizumab, ustekinumab) and CDMO work through Richter Biologics in Germany and Debrecen. Loss-making in FY2025 (Clean EBIT HUF -13,275m), it grew to HUF 53.6bn in Q1-Q3 2026 (+34.9% CER) and broke even in Q3 2026.
Strategic priorities
- Richter 2035 non-CNS growth
- Grow non-CNS revenues 7-8% a year to around EUR 3.2-3.5bn by 2035, ahead of the VRAYLAR US exclusivity end on 17 March 2030.
- Non-CNS margin of 20%+
- Lift the non-CNS Clean EBIT margin to 20%+ by 2030-31 by fixing Biotechnology, building WHC and GM portfolios and running commercial effectiveness and efficiency programmes.
- Women's Healthcare leadership and US entry
- Become the leading gynaecological company in Europe by the end of the decade, and bring FYLREVY to the US market in 2027, with a partner or alone.
- Biotechnology to break-even
- Scale biosimilar launches (denosumab, tocilizumab) toward self-sustaining operation; steady-state break-even was targeted by end-2027 and the unit broke even in Q3 2026.
- General Medicines portfolio renewal
- Return GM to steady mid-single-digit growth, driven by NOACs and a GLP-1 portfolio built with Adalvo and Hetero.
- External innovation and M&A
- Spend roughly as much on M&A and licensing as on internal R&D over 10 years, mainly in women's health, while keeping a dividend floor of about EUR 200m after the VRAYLAR LoE.
Latest results
In Q1-Q3 2026 (to 30 September), pharma revenues were HUF 686.5bn, +2.6% reported but +11.7% at constant exchange rates, as the strong forint cost about 9 percentage points. Pharma Clean EBIT rose to HUF 229.9bn (+25% CER), EBIT to HUF 216.8bn (+6.0%) and net profit to HUF 174.9bn (+7.1%), with record free cash flow of HUF 223bn. CNS revenues grew 19% CER, WHC 10.9% CER and Biotechnology 34.9% CER, while General Medicines grew only 1.4% CER. Guidance for 2026 was raised again in November 2026 to pharma revenue growth above 10% CER and high-teens pharma Clean EBIT growth (CER).
Investments and deals
- Women's health deals
- Mithra deal (EV EUR 175m, 2024) for the estetrol platform, a stake in US fertility company Granata Bio (May 2025), and the acquisition of Celmatix's women's health discovery portfolio (March 2026).
- GLP-1 partnerships
- Global semaglutide co-development with Adalvo (May 2025) and a global semaglutide partnership with Hetero (June 2026).
- API manufacturing restructuring
- Budapest API manufacturing shrinks from four plants to one half, with production concentrated in Dorog; API energy use is down 54%.
- Lenzetto capacity
- Richter is investing in manufacturing capacity because Lenzetto demand outruns supply, and repurchased earlier royalty liabilities.
- Transformation programmes
- Cloud ERP/SAP and similar transformation and restructuring costs, estimated at EUR 10-20 million for 2026, are excluded from Clean EBIT; restructuring expenses were HUF 8.8bn in Q1-Q3 2026.
Challenges and risks
- Cariprazine concentration
- Neuropsychiatry earns about three-quarters of pharma Clean EBIT, mostly from VRAYLAR royalties via AbbVie, and US exclusivity ends on 17 March 2030.
- Currency headwinds
- The strong forint cost about 9 percentage points of reported revenue growth in 2026, and FX losses cut net profit in FY2025 and H1 2026.
- US pricing and tariffs
- US drug-price pressure (Medicare renegotiation, MFN) and tariffs are flagged as strategic risks.
- Russia and Eastern Europe exposure
- Russia is the No. 2 market (HUF 137,056m in FY2025), carrying war, sanctions, supply and cash-flow risks.
- Supply and manufacturing issues
- A MYDOCALM/MYDETON out-of-stock and injectables issues hurt General Medicines, Lenzetto faces temporary stock-outs, and the USYMRO launch was put on hold over a partner's GMP issue.
What leadership says
“Hormones are the future.”
“Our commitment is to bring FYLREVY to the market in 2027”
“We are in overhead fighting mode”
“There is no other Hungary-based company with both products and personnel present on all five continents—only Richter.”
Where a supplier can help
- Manufacturing capacity and supply reliability
- Lenzetto stock-outs, the GM out-of-stock and the capacity investments point to needs in production scale-up, supply planning and quality systems.
- Efficiency and transformation services
- The non-CNS margin goal and the overhead push (centralised services, cloud ERP/SAP, R&D efficiency with AI) open doors for process, IT and automation suppliers.
- US launch support for FYLREVY
- The 2027 US launch target, with partnering in progress, creates needs in regulatory, market access and commercial launch services.
- Biosimilar commercialisation
- Biotechnology's push to break-even with new biosimilar launches and price-competitive tenders calls for pricing, tender and supply-chain support.
- FX and treasury tools
- Repeated FX losses on USD revenues are a stated headwind, a fit for hedging and treasury analytics providers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Gedeon Richter?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report 2025 (non-official PDF of the official iXBRL report)
- Gedeon Richter is a Budapest-based pharmaceutical group with 11,955 employees at end-2025 (6,097 in Hungary), present in more than 50 countries, and the largest pharma R&D centre in Central and Eastern Europe (more than 1,100 R&D employees).
- FY2025: revenues HUF 928,962m (+8.3%; EUR 2,336.1m), EBIT HUF 292,851m (+12.1%, 31.5% margin), Clean EBIT HUF 306,163m (+14.8%, 33.0% margin), net profit HUF 232,335m (-2.9%, hit by FX losses and deferred tax), free cash flow HUF 249,729m. CER growth: pharma revenues 8.3%, pharma Clean EBIT 14.2%.
- Four business units in two pillars: Innovative (Women's Healthcare, HUF 328,573m, +14.8%; Neuropsychiatry/cariprazine, HUF 264,701m, +9.0%) and Affordable (General Medicines, HUF 249,534m, -0.5%; Biotechnology, HUF 64,157m, +18.8%).
- Concentration: cariprazine (Vraylar in the US via AbbVie) earns an 87.3% Clean EBIT margin and royalty income of HUF 249,946m (USD 709.7m); US exclusivity extended by 6 months to 17 March 2030, the cliff the whole Richter 2035 strategy is built around.
- Richter 2035 targets: non-CNS revenues growing 7-8% a year to around EUR 3.2-3.5bn by 2035, non-CNS Clean EBIT margin of 20%+ by 2030-31; external innovation (M&A, licensing, mainly WHC and GM) to absorb roughly as much capital as internal R&D; minimum dividend of about EUR 200m even after the Vraylar LoE.
- Women's Healthcare is the growth engine: Ryeqo +90.5%, Lenzetto +66.7%, Drovelis +47.0%; estetrol (E4) platform from Mithra (EUR 175m EV) gave FYLREVY (DONESTA), a menopause therapy with a positive CHMP opinion in January 2026; US entry is a stated goal.
- Biotechnology (biosimilars + CDMO) is still loss-making (Clean EBIT HUF -13,275m) but launched denosumab biosimilars JUNOD/YAXWER in Europe in late 2025, with ustekinumab (USYMRO) and tocilizumab (TUYORY) to follow in 2026.
- Risks flagged: cariprazine/AbbVie dependence and US pricing (MFN, tariffs), Russia-Ukraine war (Russia is the No. 2 market, HUF 137,056m), FX (strong HUF, weak USD), General Medicines supply problems, patent litigation (Bayer on rivaroxaban).
- Half-year Report H1 2026
- H1 2026 (six months to 30 June): revenues HUF 461,596m (-0.8%), but pharma revenues grew 8.7% at constant exchange rates; the strong forint cost about 9 percentage points on reported revenue.
- EBIT HUF 143,484m (+2.2%, 31.1% margin); pharma Clean EBIT HUF 151,777m (33.3% margin); net profit HUF 103,548m (-13.7%) after FX losses of HUF 27.1bn; free cash flow a strong HUF 137,038m (+23.7%).
- Guidance raised: 2026 profitability now double-digit Clean EBIT growth (CER), on Vraylar outperformance and efficiency gains; revenue target unchanged at high-single-digit CER growth.
- CNS: cariprazine HUF 132,959m (+6.9%; CER +22% for CNS revenues); AbbVie's Vraylar sales USD 1.98bn in H1 (+19%); Clean EBIT HUF 113,771m.
- WHC flat at HUF 167,304m (CER +7.1%) as Russia (-15.2%) and China (-31.8%) fell; Ryeqo +61.6%, Lenzetto +46.4%, Drovelis +28.2%; FYLREVY launched in pilot European markets; Celmatix discovery portfolio acquired.
- BIO +19.6% to HUF 35,212m; Clean EBIT loss cut to HUF -1,971m from HUF -8,535m; TUYORY (tocilizumab) approved in April 2026; USYMRO launch on hold over Bio-Thera GMP issue.
- GM -10.3% to HUF 117,410m (OTC -28.3% on a weak flu season, Poland -26.5%, Russia -10.4%); semaglutide generic deal with Hetero.
- 2025 dividend: HUF 120,000m (HUF 96,600m regular + HUF 23,400m special); RGH-202 cleared for a US Phase II in social anxiety disorder.
- Q3 2026 Earnings Report
- Q1-Q3 2026 (to 30 September, published 10 November 2026): pharma revenues HUF 686.5bn, +2.6% reported but +11.7% at constant exchange rates; FX cost about 9 percentage points.
- Pharma Clean EBIT HUF 229.9bn (+7.9% reported, +25% CER); EBIT HUF 216.8bn (+6.0%); net profit HUF 174.9bn (+7.1%); EPS HUF 956; record free cash flow HUF 223bn (+12%).
- 2026 guidance raised again: pharma revenues above 10% CER growth, pharma Clean EBIT high-teens CER growth.
- CNS revenues HUF 202.0bn (CER +19%); Vraylar royalty HUF 189bn; AbbVie raised Vraylar 2026 sales guidance to about USD 4.2bn; Reagila +27% to HUF 13.2bn.
- WHC HUF 251.5bn (CER +10.9%, Q3 +19.2%); UF/EM grew over 50% and Menopause about 30% (CER); Lenzetto faces stock-outs as capacity expands; FDA accepted the US filing for FYLREVY.
- BIO revenue HUF 53.6bn (CER +34.9%) and broke even in Q3; tocilizumab biosimilar launched in Q3.
- GenMed HUF 176.1bn (CER +1.4%), with a strong Q3 rebound (+16.6% CER) but OTC still down 18.7% YTD.
- Q2 2026 earnings call transcript
- H1/Q2 2026 results call, 7 August 2026, with CEO Gábor Orbán and CFO László Kovács.
- CER revenue growth reached 8.7% in H1 and CER Clean EBIT rose 21%; 2026 Clean EBIT guidance raised to double-digit ("somewhere in the teens"), helped by Vraylar, biotech near break-even and efficiency programmes.
- API restructuring: Budapest API manufacturing shrinks from four plants to "one half", consolidating in Dorog; API energy use down 54%.
- WHC Clean EBIT margin 18.5% in H1, flagged as exceptional; the target of 20% will not come "overnight". FYLREVY US commitment: market in 2027, filing and partnering in progress.
- GenMed is the only unit below plan; return to steady mid-single-digit growth expected from next year, driven by NOACs. GLP-1s fit the women's health and longevity story; generic semaglutide launches mostly in the 2030s.
- Capital allocation: shareholders favour dividends over buybacks; M&A, primarily women's health, is the priority use of net cash.
- RGH-202 enters Phase II in social anxiety disorder; partnering expected after proof-of-concept data in about two years.
- Q4 2025 earnings call transcript
- Q4 2025 results call, 26 February 2026, with CEO Gábor Orbán and CFO László Kovács.
- 2025 was "a challenging year": tariffs, US drug-price pressure, a weak dollar and strong forint. Year-end brought relief: US pricing settled at a "manageable" level and Vraylar exclusivity was extended by six months, leaving "exactly four more years".
- Orbán sees a major shift in sentiment toward hormone therapy and says "Hormones are the future"; estetrol (FYLREVY) to launch first in Hungary and nearby countries, then northern Europe in H2 2026.
- Women's Health was +15% and Ryeqo and Lenzetto grew 75% in 2025; Lenzetto demand outruns manufacturing, so Richter is investing in capacity.
- BIO posted its first quarterly profit (HUF 0.5bn); break-even targeted by end-2027. GenMed recovery from the Q3 2025 stock-out will be protracted.
- 2026 guidance: high-single-digit growth in revenues and Clean EBIT; R&D to rise to 11% of sales; restructuring costs (EUR 10-20 million in 2026) to be excluded from Clean EBIT.
- M&A: sellers pulled deals in 2025, so cash builds up; most targets are in Women's Health, otherwise surplus cash flows into dividends.
- Richter Set to Lead Europe in Gynaecology — An Interview with CEO Gábor Orbán
- Interview of CEO Gábor Orbán by Hungarian Conservative, 26 May 2025, recorded on the sidelines of the Free Market Road Show in Budapest.
- Ambition: "by the end of the decade, Richter is well positioned to become the leading gynaecological company in Europe"; in contraception it already holds a market-leading position.
- Cariprazine is the only original drug from an Eastern European company launched in the US and the only one to reach blockbuster status; it is used for schizophrenia and bipolar disorder.
- US pricing pressure is real: Medicare price caps and mandatory renegotiation (started 1 January 2025) and a Trump executive order to bring US prices closer to Europe's.
- Strategy to the 2030s: use cariprazine's cash to build a more balanced business; four pillars (gynaecology, original psychiatry research with partners, biotechnology, CEE generics) grouped as 'Innovative' and 'Affordable' in the 2025-2035 strategy.
- Eastern markets (Russia, Kazakhstan, Uzbekistan) have less competition but smaller potential than the US; Richter is the only Hungary-based company with products and staff on all five continents.
Questions about Gedeon Richter
What does Gedeon Richter do?
Gedeon Richter is a Hungarian pharmaceutical group that develops, manufactures and sells original drugs, generics, biosimilars and CDMO services. Its four units are Women's Healthcare, Neuropsychiatry, General Medicines and Biotechnology.
What is Gedeon Richter's revenue?
FY2025 revenues were HUF 928,962m (EUR 2,336.1m), up 8.3%. In Q1-Q3 2026 pharma revenues were HUF 686.5bn, +11.7% at constant exchange rates.
How many employees does Gedeon Richter have?
It had 11,955 employees at end-2025, 6,097 of them in Hungary, with more than 1,100 working in R&D.
What is Gedeon Richter's strategy?
Richter 2035 aims to grow non-CNS revenues to around EUR 3.2-3.5bn by 2035 and lift the non-CNS Clean EBIT margin to 20%+ by 2030-31, preparing for the end of VRAYLAR US exclusivity in 2030. Women's Healthcare is the main growth and M&A focus.
Who leads Gedeon Richter?
Gábor Orbán has been CEO since 2017 and László András Kovács is CFO. Prof. Dr. E. Szilveszter Vizi chairs the Board.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)